Pfizer is buying Toronto and Cambridge, Massachusetts-based Trillium Therapeutics in a deal worth $2.26 billion. Trillium focuses on developing a new set of checkpoint inhibitors to treat cancer.
GlaxoSmithKline’s entire stake in Innoviva was sold back to the U.S.-based biopharmaceutical company for about $392 million, the British drugmaker said on May 20, as GSK simplifies operations ahead of a split into two businesses.
Sanofi SA said the company would sell its stake in Regeneron Pharmaceuticals Inc., but would not change their ongoing collaboration.
Bristol-Myers Squibb and Israel’s Compugen will collaborate in clinical trials for patients with advanced solid tumors.
Pershing Square, a hedge fund run by activist investor William Ackman, and Valeant decided to settle an insider trading lawsuit with Allergan and pay $290 million.
SEC Filing Reveals GlaxoSmithKline’s 13 Percent Stake in Spero Therapeutics
Antibiotics, Antimicrobials, Bacterial Infections, Biomedical Advanced Research and Development Authority (BARDA), Biotech, Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), Department of Defense, Department of Health and Human Services (HHS), Filings, National Institute of Allergy and Infectious Diseases (NIAID), SEC, Shares, StakesA filing with the U.S. Securities and Exchange Commission (SEC) indicates that the UK’s GlaxoSmithKline has a 13 percent stake in Spero Therapeutics, with 1,854,006 shares in the Massachusetts biotech company.
Basel, Switzerland-based Novartis has decided not to sell its $14 billion stake in Swiss rival Roche.